WinstonWınston
Aditxt logo

Aditxt

ADTX
6
Biotechnology · Healthcare
Price
$0.00
+0.00 (+13.42%)
Market Cap
$3.0M
Exchange
Other OTC
Winston Score
6
Winston is worried
Weak fundamentals across most pillars.
Based on the IPO prospectus (annual filing). This score will refine automatically once the company reports its first quarters.

Share count rising — dilution

+183.5% over 1y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 13K (2024) → 37K (2025)

Aditxt, Inc. is a small biotechnology company focused on immune system monitoring and modulation. Its main technology, called AditxtScore, is designed to measure how a person's immune system is responding — for example, after a vaccine or organ transplant. The company targets healthcare providers, researchers, and potentially pharmaceutical companies looking for better tools to track immune health.

Aditxt generates revenue through laboratory services and licensing of its immune monitoring platform, though it currently spends far more than it earns, resulting in deep operating losses. The company operates primarily in the United States and has a very small market presence. Its financial metrics, including a sharply negative return on invested capital, reflect the early and high-risk stage of the business. The key challenge ahead is proving that its immune monitoring technology works well enough to attract paying customers at scale and securing enough funding to continue operations before cash runs out.

Winston Score History

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

>+1,000% YoY

YoY Growth Rate

Revenue accelerating

EPS Growth

<−1,000% YoY

YoY Growth Rate

Earnings declining

R&D Spend

$3M/ year

Declining (-71% vs prior year)

>1,000% of revenue

5554.0x the sector average (18%)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

100.0%ownership

Insiders own a meaningful stake in the company

Cash Runway

~7 months

$11M cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

Short runway — potential dilution ahead through share issuance

Revenue accelerating

Aditxt grew revenue 1094% year-over-year and the growth rate is speeding up. That's the kind of momentum growth investors look for — the question is whether margins can follow.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin
8.4%
Thin — 8.4% gross margin
Operating Margin
-612542.2%
Losing money on operations — -612542.2%
ROCE
-262.2%
Weak — -262.2% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY
-97.6%
Shrinking sales (-97.6% YoY)
EPS YoY
N/A
Data not available
EPS Consistency
N/A
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion
N/A
Data not available
FCF Margin
-804447636.9%
Burning cash (-804447636.9%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity
0.33
Conservative — low debt load (0.33)
Interest Cover
N/A
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)
N/M
Negative earnings — P/E not meaningful
P/E vs Forward
N/A
not available
Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial